CTKB · Cytek Biosciences, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA loss non-GAAP | $1.5M | the second quarter of 2026 | — |
|
|
|||
| Non-GAAP adjusted gross margin non-GAAP | 56% | Six months ended June 30, 2026 | — |
| Non-GAAP adjusted gross profit non-GAAP | $52.04M | Six months ended June 30, 2026 | — |
| Recurring revenue as a percentage of total revenue (trailing-12-month basis) | 35% | the second quarter of 2026 | — |
| Total installed base of Cytek instruments | 3,933 | the second quarter of 2026 | — |
|
|
|||
| Total recurring revenue, comprised of service and reagent revenues | $18.5M | the second quarter of 2026 | — |
| Units added to installed base | 142 | the second quarter of 2026 | — |
| Adjusted EBITDA non-GAAP | $4.5M | Q4 2025 | — |
| Adjusted EBITDA excluding investment income non-GAAP | -$3.1M | Full Year 2025 | — |
| Total instruments placed | 630 | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTKB
this stock
Cytek Biosciences, Inc.
|
$623.92M | -7.7% | +6414.2% | — | 3.8% |
|
ABT
Abbott Laboratories
|
$198.81B | -8.9% | +5.7% | 32.0 | 1.3% |
|
SYK
Stryker Corp
|
$127.26B | -6.8% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$120.49B | -3.9% | +8.4% | 25.2 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -48.2% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTKB | -4.7% | +2.2% | +4.0% | +10.4% | -7.7% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -2.7% | -1.1% | -7.2% | +8.4% | -19.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.